Sauveur-Michel Maira

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

Anna Dubrovska, Sungeun Kim, Richard J. Salamone et al. · Proceedings of the National Academy of Sciences · 2008 · 562 citations · Full text

Lineage Plasticity, Developmental Biology, Pi3k Activity +14

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 524 citations

Pharmacotherapy, Different Selectivity Profile, Chemical Biology +26

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday et al. · Molecular Cancer Therapeutics · 2014 · 462 citations

Pten Mutation, Somatic Pik3ca Mutations, Pharmacotherapy +18

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

Saskia M. Brachmann, Irmgard Hofmann, Christian Schnell et al. · Proceedings of the National Academy of Sciences · 2009 · 316 citations · Full text

Dual Pi3k/mtor Inhibitor, Breast Oncology, Oncology +15